Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2021 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.
Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.
The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.
| Resolution | For: | %age | Against: | %age | Withheld |
| 1. To receive a copy of the Annual Report for the year ended 30 June 2021 | 176,577,712 | 99.99 | 0 | 0 | 0 |
| 2. To approve the Directors' Remuneration Report | 174,524,577 | 98.86 | 1,989,308 | 1.13 | 63,827 |
| 3. To re-appoint Mary Tavener as a Director | 176,161,541 | 99.98 | 7,089 | 0.01 | 409,082 |
| 4. To re-appoint Scott Leinenweber as a Director | 173,381,457 | 98.41 | 2,787,173 | 1.58 | 409,082 |
| 5. To re-appoint Tunde Otulana as a Director | 176,161,541 | 99.98 | 7,089 | 0.01 | 409,082 |
| 6. To re-appoint Peter Jensen as a Director | 173,387,212 | 98.84 | 2,022,948 | 1.15 | 1,167,552 |
| 7. To appoint BDO LLP as auditors of the Company | 176,142,079 | 99.97 | 32,806 | 0.02 | 402,827 |
| 8. To authorise the Directors to determine the Auditors remuneration | 176,577,712 | 99.99 | 0 | 0 | 0 |
| 9. To authorise the Directors to allot unissued share capital up to a specified amount (s551) | 176,565,019 | 99.98 | 11,693 | 0.01 | 1,000 |
| 10 Special Resolution: To disapply pre-emption provisions of s561(1) of the CoAct 2006 up to a specified amount | 37,107,171 | 21.00 | 139,469,541 | 78.99 | 1,000 |
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
